169 related articles for article (PubMed ID: 11753975)
81. Relationship among cystectomy, microvessel density and prognosis in stage T1 transitional cell carcinoma of the bladder.
Dinney CP; Babkowski RC; Antelo M; Perrotte P; Liebert M; Zhang HZ; Palmer J; Veltri RW; Katz RL; Grossman HB
J Urol; 1998 Oct; 160(4):1285-90. PubMed ID: 9751337
[TBL] [Abstract][Full Text] [Related]
82. Overexpression of clusterin in transitional cell carcinoma of the bladder is related to disease progression and recurrence.
Miyake H; Gleave M; Kamidono S; Hara I
Urology; 2002 Jan; 59(1):150-4. PubMed ID: 11796313
[TBL] [Abstract][Full Text] [Related]
83. [Radical cystectomy in patients with pathological non-muscle invasive bladder cancer].
Hao H; Su XH; Zheng W; Ge P; He Q; Shen Q; Yang XY; Zhang Z; Li XS; Lin J; Zhou LQ
Beijing Da Xue Xue Bao Yi Xue Ban; 2016 Aug; 48(4):627-631. PubMed ID: 29263502
[TBL] [Abstract][Full Text] [Related]
84. Absence of Tumor on Repeat Transurethral Resection of Bladder Tumor Does Not Predict Final Pathologic T0 Stage in Bladder Cancer Treated with Radical Cystectomy.
Kukreja JB; Porten S; Golla V; Ho PL; Noguera-Gonzalez G; Navai N; Kamat AM; Dinney CPN; Shah JB
Eur Urol Focus; 2018 Sep; 4(5):720-724. PubMed ID: 28753837
[TBL] [Abstract][Full Text] [Related]
85. [Transitional cell carcinoma of the bladder. Evaluation of plasma levels of cellular fibronectin as a stage-dependent marker].
Hegele A; Kosche B; Schrader AJ; Sevinc S; Olbert PJ; Hofmann R; Kropf J
Urologe A; 2008 Sep; 47(9):1137-40. PubMed ID: 18651122
[TBL] [Abstract][Full Text] [Related]
86. Elevated serum levels of transforming growth factor-beta1 in patients with colorectal carcinoma: its association with tumor progression and its significant decrease after curative surgical resection.
Shim KS; Kim KH; Han WS; Park EB
Cancer; 1999 Feb; 85(3):554-61. PubMed ID: 10091729
[TBL] [Abstract][Full Text] [Related]
87. Monitoring Treatment Response and Metastatic Relapse in Advanced Bladder Cancer by Liquid Biopsy Analysis.
Birkenkamp-Demtröder K; Christensen E; Nordentoft I; Knudsen M; Taber A; Høyer S; Lamy P; Agerbæk M; Jensen JB; Dyrskjøt L
Eur Urol; 2018 Apr; 73(4):535-540. PubMed ID: 28958829
[TBL] [Abstract][Full Text] [Related]
88. Significance of serum soluble Fas ligand in patients with bladder carcinoma.
Mizutani Y; Hongo F; Sato N; Ogawa O; Yoshida O; Miki T
Cancer; 2001 Jul; 92(2):287-93. PubMed ID: 11466681
[TBL] [Abstract][Full Text] [Related]
89. Plasma level of transforming growth factor beta1 measured from the azygos vein predicts prognosis in patients with esophageal cancer.
Fukuchi M; Miyazaki T; Fukai Y; Nakajima M; Sohda M; Masuda N; Manda R; Tsukada K; Kato H; Kuwano H
Clin Cancer Res; 2004 Apr; 10(8):2738-41. PubMed ID: 15102678
[TBL] [Abstract][Full Text] [Related]
90. [Complete resection of urothelial cancer metastases with curative intent].
Lehmann J; Suttmann H; Albers P; Volkmer B; Gschwend JE; Fechner G; Spahn M; Heidenreich A; Odenthal A; Seif C; Nürnberg N; Wülfing C; Greb C; Kälble T; Grimm MO; Fieseler CF; Krege S; Retz M; Schulte-Baukloh H; Gerber M; Hack M; Kamradt J; Stöckle M
Urologe A; 2009 Feb; 48(2):143-50. PubMed ID: 19142626
[TBL] [Abstract][Full Text] [Related]
91. Clinical outcomes of muscle invasive bladder Cancer according to the BASQ classification.
Yuk HD; Jeong CW; Kwak C; Kim HH; Moon KC; Ku JH
BMC Cancer; 2019 Sep; 19(1):897. PubMed ID: 31500577
[TBL] [Abstract][Full Text] [Related]
92. Clinical significance of routine pre-cystectomy bone scans in patients with muscle-invasive bladder cancer.
Braendengen M; Winderen M; Fosså SD
Br J Urol; 1996 Jan; 77(1):36-40. PubMed ID: 8653315
[TBL] [Abstract][Full Text] [Related]
93. Serum levels of transforming growth factor beta1 in patients with breast cancer.
Sheen-Chen SM; Chen HS; Sheen CW; Eng HL; Chen WJ
Arch Surg; 2001 Aug; 136(8):937-40. PubMed ID: 11485532
[TBL] [Abstract][Full Text] [Related]
94. Elevated plasma levels of transforming growth factor-beta 1 (TGF-beta 1) in patients with advanced breast cancer: association with disease progression.
Ivanović V; Todorović-Raković N; Demajo M; Nesković-Konstantinović Z; Subota V; Ivanisević-Milovanović O; Nikolić-Vukosavljević D
Eur J Cancer; 2003 Mar; 39(4):454-61. PubMed ID: 12751375
[TBL] [Abstract][Full Text] [Related]
95. Urinary concentration of human chorionic gonadotrophin and its fragments as a prognostic marker in bladder cancer.
Iles RK; Persad R; Trivedi M; Sharma KB; Dickinson A; Smith P; Chard T
Br J Urol; 1996 Jan; 77(1):61-9. PubMed ID: 8653319
[TBL] [Abstract][Full Text] [Related]
96. Tumor cell-derived TGF-β at tumor center independently predicts recurrence and poor survival in oral squamous cell carcinoma.
Lu Z; Ding L; Ding H; Hao F; Pu Y; Wang Y; Chen S; Yang Y; Zhao X; Huang X; Zhang L; Wang Z; Hu Q; Ni Y
J Oral Pathol Med; 2019 Sep; 48(8):696-704. PubMed ID: 31141218
[TBL] [Abstract][Full Text] [Related]
97. Outcome of the treatment of invasive non-transitional cell carcinoma.
Girgin C; Sezer A; Uc R; Ermete M; Ozkan U; Gurel G
Int J Urol; 2003 Oct; 10(10):525-9. PubMed ID: 14516399
[TBL] [Abstract][Full Text] [Related]
98. [Sarcomatoid carcinoma of the bladder in a 25-year-old man].
Kunz J; Reinke J; Schmidt A; Althaus P; Oesterwitz H
Pathologe; 1995 Nov; 16(6):426-30. PubMed ID: 8570563
[TBL] [Abstract][Full Text] [Related]
99. Plasma transforming growth factor-beta 1 reflects disease status in patients with lung cancer after radiotherapy: a possible tumor marker.
Kong FM; Washington MK; Jirtle RL; Anscher MS
Lung Cancer; 1996 Dec; 16(1):47-59. PubMed ID: 9017584
[TBL] [Abstract][Full Text] [Related]
100. [Plasma E-cadherin levels in urinary bladder cancer: does it improve risk stratification?].
Szarvas T; Hoffmann F; Becker M; Schenck M; Vom Dorp F; Rübben H; Jäger T
Urologe A; 2011 Jan; 50(1):64-70. PubMed ID: 21153394
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
